AbCellera Biologics Inc. (ABCL)
NMS · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 9.0M | 44.9M | 8.3M | 4.0M |
| Operating Income | (73.5M) | (25.3M) | (53.2M) | (58.9M) |
| Net Income | (57.1M) | (8.9M) | (43.2M) | (55.4M) |
| Diluted EPS | $-0.19 | N/A | $-0.14 | $-0.18 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 485.4M | 38.0M | 28.8M | 75.1M |
| Gross Profit | 419.0M | 38.0M | 28.8M | |
| Operating Income | 227.1M | (223.1M) | (301.1M) | (203.2M) |
| Net Income | 158.5M | (146.4M) | (162.9M) | (146.4M) |
| Diluted EPS | $0.50 | $-0.51 | $-0.55 | $-0.49 |